SCHEDULE: FMR LLC Discloses Stake in Inovio Pharmaceuticals

FMR LLC, through its subsidiaries, reports beneficial ownership of 13.5% of Inovio Pharmaceuticals Inc. common stock as of March 31, 2026.

Summary

• FMR LLC, along with Abigail P. Johnson and other affiliated entities, has filed a Schedule 13G, indicating their beneficial ownership of Inovio Pharmaceuticals Inc. common stock.
• As of March 31, 2026, the total beneficial ownership reported is 9,339,614 shares, representing 13.5% of the class of securities.
• Fidelity Management & Research Company LLC and Strategic Advisers LLC are identified as investment advisers holding significant portions of these shares.
• Abigail P. Johnson, as CEO and Chairman of FMR LLC, and other members of the Johnson family, hold voting power through a shareholders' voting agreement concerning FMR LLC's Series B voting common shares.
• The filing clarifies that this report pertains to securities held in the ordinary course of business and not for the purpose of influencing control of Inovio Pharmaceuticals Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a significant passive investment by a major financial institution, but provides no new operational or strategic information about Inovio Pharmaceuticals Inc. itself.

Positives

• FMR LLC, a significant investment management firm, has a substantial stake in Inovio Pharmaceuticals Inc., indicating confidence from a major financial institution.
• The reported ownership of 13.5% suggests a notable investment position, potentially signaling a belief in the company's future prospects by the reporting entities.

Negatives

• The filing is a Schedule 13G, which is an informational filing for passive investors, and does not indicate any active management or control intentions, which could be seen as a lack of direct strategic involvement.
• The disclosure of a significant stake by a large investment firm does not inherently guarantee positive future performance for Inovio Pharmaceuticals Inc.

Risks

• The filing does not explicitly mention any risks associated with Inovio Pharmaceuticals Inc. or the investment itself. The risks are inherent to any equity investment and the specific business of the issuer.

Future Outlook

This filing is an informational disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Inovio Pharmaceuticals Inc.'s future performance.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters..."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities..."

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by FMR LLC, a major asset manager, indicates a significant passive investment in Inovio Pharmaceuticals Inc. Such filings by large institutional investors can signal market interest but do not necessarily reflect a strategic partnership or control intent.

Stakeholder Impact

• Shareholders: The filing confirms a significant passive stake held by FMR LLC, which may be viewed positively by some investors as an indication of institutional interest. However, it does not directly impact current operations or strategy.
• Management of Inovio Pharmaceuticals Inc.: The filing is informational and does not require direct action from Inovio's management, other than acknowledging the reporting requirements.
• Other Investors: The disclosure provides transparency regarding the ownership structure, allowing other market participants to be aware of FMR LLC's position.

Next Steps

• FMR LLC and its affiliates will continue to hold their beneficial ownership of Inovio Pharmaceuticals Inc. common stock.
• Future filings will be made if ownership levels change significantly or if the nature of the holding changes from passive to active.

Key Dates

Keywords

Inovio Pharmaceuticals, FMR LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Fidelity Management & Research Company LLC, Strategic Advisers LLC, Abigail P. Johnson, SEC Filing